{"id":"iv-tulisokibart","safety":{"commonSideEffects":[{"rate":null,"effect":"Flu-like symptoms"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL5095370","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a toll-like receptor 7 (TLR7) agonist, tulisokibart binds to TLR7 on immune cells, triggering downstream signaling that promotes dendritic cell maturation and T-cell activation. This mechanism is designed to enhance the body's intrinsic anti-tumor immune response, potentially synergizing with checkpoint inhibitors or other immunotherapies.","oneSentence":"Tulisokibart is a TLR7 agonist that activates innate immune responses to enhance anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:27.871Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)"}]},"trialDetails":[{"nctId":"NCT06430801","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-05","conditions":"Crohn's Disease","enrollment":1200},{"nctId":"NCT06052059","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-10-25","conditions":"Ulcerative Colitis","enrollment":1020},{"nctId":"NCT05270668","phase":"PHASE2","title":"Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2022-03-29","conditions":"Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease","enrollment":154},{"nctId":"NCT04996797","phase":"PHASE2","title":"A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)","status":"COMPLETED","sponsor":"Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2021-07-14","conditions":"Ulcerative Colitis","enrollment":178},{"nctId":"NCT06829225","phase":"PHASE1","title":"Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-13","conditions":"Colitis, Ulcerative","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PRA023","MK-7240"],"phase":"phase_3","status":"active","brandName":"IV Tulisokibart","genericName":"IV Tulisokibart","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tulisokibart is a TLR7 agonist that activates innate immune responses to enhance anti-tumor immunity. Used for Advanced or metastatic solid tumors (in combination with checkpoint inhibitors).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}